The Singapore Bariatric Surgery Devices Market was valued at $3.2 Mn in 2023 and is projected to grow at a CAGR of 5.8% from 2023 to 2023, to $4.7 Mn by 2030. The growing prevalence of adult obesity brought on by changed lifestyle choices and excessive calorie consumption are major drivers propelling the market for bariatric surgical devices. Increased government support and rising public awareness of the unhealthy food and beverage options available in the market and how they affect BMI are expected to fuel the need for bariatric surgeries over the course of the forecast period, which will also propel the expansion of the bariatric surgery devices market. The prominent players in the market are Zimmer Biomet, Boston Scientific, Medtronic, B. Braun, Asenus Surgical, Johnson & Johnson, Cousin Surgery among others.
Singapore CT Scan Market was valued at $5.53 Mn in 2023 and is predicted to grow at a CAGR of 8.47% from 2023 to 2030, to $9.77 Mn by 2030. The key drivers of this industry include rising affluence and healthcare expenditure, the growing burden of chronic diseases, and the aging population. The industry is primarily dominated by GE HealthCare, Siemens Healthineers, Canon Medical Systems, and NeuroLogica Corp. among others.
The Singapore Mental Health Apps Market was valued at $7.44 Mn in 2023 and is predicted to grow at a CAGR of 15.8% from 2023 to 2030, to $20.77 Mn by 2030. The key drivers of this industry include increasing smartphone penetration, rising awareness, and government support. The industry is primarily dominated by players such as Calm, Happify, Headspace, and MindFi among others.
The Singapore Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.5% during the forecast period, rising from $8 Mn in the year 2022 and reaching $13 Mn by the year 2030. Factors contributing to the Singapore Actinic Keratosis Therapeutic Market growth include rising healthcare expenditures, an aging population, changing weather patterns, and patient preferences for convenient and effective treatment modalities. Key players in the Singapore Actinic Keratosis Therapeutic Market include LEO Pharma, Galderma, Sun Pharmaceuticals, Bayer, Alma Lasers, Syneron Candela, Novartis and Bausch Health among others
Singapore Constipation Therapeutics Market was valued at $22 Mn in 2022 and is estimated to reach $38 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The global growth of the constipation therapeutics market is driven by factors such as aging, sedentary lifestyles, and unhealthy dietary habits. The increasing elderly population, susceptible to chronic conditions, notably contributes to this expansion. Major players in this sector comprise GlaxoSmithKline, Johnson & Johnson, Sanofi, Abbott, Bayer, AstraZeneca, Pfizer, Merck Sharp & Dohme, Boehringer Ingelheim, and United Laboratories.
The Singapore Herbal Supplements Market was valued at $6.31 Mn in 2023 and is predicted to grow at a CAGR of 6.8% from 2023 to 2030, to $10 Mn by 2030. The key drivers of this industry include an aging population, increasing health awareness, and the prevalence of lifestyle diseases. The industry is primarily dominated by players such as Himalaya Wellness, Herbalife, Amway, and NOW Foods among others.
Singapore Brain Cancer Therapeutics Market valued at $3 Mn in 2022, projected to reach $6 Mn by 2030 with a 11.2% CAGR. Anticipated increases in the occurrence of brain cancer, particularly glioblastoma multiforme, are expected to substantially boost the need for treatments targeting brain cancer, thereby impacting the market's overall landscape. Currently, prominent pharmaceutical entities in the market include Merck & Co, Avatamed, Amgen, Roche, Pfizer, A*STAR, AUM Biosciences, Novartis, AstraZeneca, and Mirati Therapeutics.
Singapore Clinical Nutrition for Chronic Kidney Diseases Market was valued at $1.90 Mn in 2023 and is predicted to grow at a CAGR of 6.63% from 2023 to 2030, to $3.00 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Singapore Blood Disorder Therapeutics Market valued at $16 Mn in 2022, projected to reach $30 Mn by 2030 with a 8.1% CAGR. The market is expanding due to the rising prevalence of blood disorders brought on by aging populations and unhealthy lifestyle choices, therapeutic advancements supported by technology developments, and government programs that fund research and provide affordable therapies. The Singapore Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda, Sanofi, Novo Nordisk, CSL Ltd, Pfizer, Bayer, BioLife Sciences, Agenus, Spark Therapeutics, Abeo Therapeutics, etc, among various others.
Singapore Dental Endodontics Market was valued at $2.10 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030, to $2.90 Mn by 2030. The key drivers of this industry include high dental awareness and focus on preventive care, rising disposable income, growing demand for cosmetic dentistry, and dental tourism. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
Singapore Cancer Induced Bone Disease Therapeutics Market valued at $2 Mn in 2022, projected to reach $3 Mn by 2030 with a 6.4% CAGR. The key drivers of this industry include the rising incidence of cancer, technological advancements, and increased government funding. The industry is primarily dominated by players such as Radius Health, Bayer, Merck, Eli Lilly, Teva, Johnson & Johnson, Amgen, and Novartis among others.
The Singapore Clinical Nutrition Market was valued at $36.8 Mn in 2023 and is projected to grow at a CAGR of 5.94% from 2023 to 2023, to $55.1 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as iX Biopharma, NTUC Health, Baxter, Abbott Nutrition, Pfizer Inc, Nestle, Baxter International Inc. among others.
Singapore Digital Biomarkers Market was valued at $3.48 Mn in 2023 and is predicted to grow at a CAGR of 22.9% from 2023 to 2030, to $14.74 Mn by 2030. The key drivers of this industry include a high disease burden, a tech-savvy population, government support, and a focus on preventative care. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
The Singapore Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $12 Mn in 2022 to $20 Mn by 2030, with a CAGR of 6.4% during the forecast period of 2022-2030. The key drivers of the market in Singapore include the rising prevalence of CVD risk factors due to the urban lifestyle, increasing healthcare expenditure supported by government prioritization, and enhanced research and development activities establishing Singapore as a regional hub for life sciences innovation. The Singapore Congestive Heart Failure Therapeutics Market hosts various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, Pfizer, Singapore Technologies Pharmaceuticals, AStar, Biostadt Pharmaceuticals, etc., among various others.
Singapore Cardiac Resynchronization Therapy Market valued at $6 Mn in 2022, projected to reach $9 Mn by 2030 with a 5.6% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
The Singapore Physiotherapy Equipment Market was valued at $25.08 Mn in 2023 and is predicted to grow at a CAGR of 7.8% from 2023 to 2030, to $42.43 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic diseases, expanding geriatric population, and advancements in technology. The key players in the industry are Joyson Health, EMS Physio Ltd., and Forefront Medical Technology among others.
Singapore Cardiac Arrhythmia Therapeutics Market valued at $9 Mn in 2022, projected to reach $14 Mn by 2030 with a 6.4% CAGR. The key drivers of this industry include the rising incidence of cardiac arrhythmias, government initiatives, and technological advances. The industry is primarily dominated by players such as Abbott, Philips Healthcare, Boston Scientific, Acutus, Siemens, Affectis, and Medtronic among others.
The Singapore Biosensors Market was valued at $34.7 Mn in 2023 and is predicted to grow at a CAGR of 8.6% from 2023 to 2030, to $61.8 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, emphasis on preventative care, and technological advancements. The prominent players of the Singapore Biosensors Market are Grip Molecular Technologies, Bio-Rad International, and Biosensors International, among others.
The Singapore Medical Digital Imaging System Market was valued at $36.6 Mn in 2023 and is predicted to grow at a CAGR of 8.8% from 2023 to 2030, to $66.05 Mn by 2030. The key drivers of this industry include healthcare expenditure, advanced healthcare infrastructure, and technological innovations. The industry is primarily dominated by players such as Siemens Healthineers, GE Healthcare, Philips Healthcare, and Canon Medical Systems among others.
The Singapore Central Nervous System (CNS)Therapeutics Market was valued at $252 Mn in 2022 and is predicted to grow at a CAGR of 7% from 2023 to 2030, to $433 Mn by 2030. The key drivers of this industry include the increasing prevalence of CNS disorders, increasing government initiatives, and growing awareness and diagnoses. The industry is primarily dominated by players such as AbbVie, Novartis, Merck, AstraZeneca, Teva, and Eli Lilly among others.